Dexcom's third quarter 2026 revenue and earnings beat estimates as full-year guidance was raised

Dexcom reported third quarter 2026 revenue of $1.34 billion, an 11% increase year-over-year, surpassing the analyst consensus of $1.32 billion. Non-GAAP diluted EPS reached $0.73, beating the $0.66 estimate, driven by strong growth in the U.S. market and significant expansion in operating margins.

Key Highlights

• Total revenue grew 11% to $1.344 billion, with U.S. revenue increasing 14% and international revenue growing 5%.
• Non-GAAP operating margin expanded by 270 basis points year-over-year to 25.3% of reported revenue.
• Management raised the fiscal year 2026 revenue guidance midpoint to a range of $5.20–$5.25 billion.
• The Board of Directors authorized a new share repurchase program of up to $1.0 billion through December 2027.